艾司西酞普兰联合黛力新治疗卒中后抑郁患者临床疗效分析  

Analysis on clinical curative effect of escitalopram combined with deanxitin treatment of patients with post-stroke depression

作　　者：刘得水[1] 李丽波[1] 荣华[1] 兴桂华[1] 张晓杰[1] 高志影[1] MU Deshui;LI Libo;RONG Hua;XING Guihua;ZHANG Xiaojie;GAO Zhiying(Qiqihar Medical University,Qiqihar 161000,China)

机构地区：[1]齐齐哈尔医学院,黑龙江省齐齐哈尔161000

出　　处：《中国医药科学》2018年第20期7-10,共4页China Medicine And Pharmacy

基　　金：黑龙江省教育厅面上项目(2016-KYYWF-0871)

摘　　要：目的研究艾司西酞普兰联合黛力新治疗卒中后抑郁的疗效和安全性。方法 2016年3月～2018年3月随机抽取齐齐哈尔医学院附属第三医院收治的64例卒中后抑郁患者分为对照组和研究组,每组各32例,两组患者均给予常规治疗,在此基础上对照组仅服用艾司西酞普兰,研究组联合应用艾司西酞普兰和黛力新,共治疗6周。采用汉密顿抑郁量表(HAMD)、美国国立卫生研究院卒中量表(NIHSS)评估两组患者的临床疗效,并采用酶联免疫吸附法(ELISA)对两组患者神经生长因子(NGF)和脑源性神经营养因子(BDNF)两种神经细胞因子进行检测。结果研究组总有效率为93.8%,明显高于对照组(χ~2=5.379,P<0.05);研究组治疗后第2、4、6周HAMD评分(15.54±3.28,t=2.287;12.35±2.57,t=4.826;8.93±3.17,t=4.286)和NIHSS评分(9.39±2.27,t=2.304;7.31±2.23,t=2.745;5.95±1.82,t=2.643)也均低于对照组(P <0.05);两组患者治疗后血清NGF(13.37±1.18)和BDNF(16.13±1.67)表达水平均较高于治疗前(t=11.533,P <0.05),且研究组血清NGF和BDNF表达水平均显著高于对照组(t=7.172,P <0.05)。结论艾司西酞普兰联合黛力新能够显著改善卒中后抑郁患者抑郁症状和神经功能,提高神经因子表达水平,值得临床推广。Objective To study the curative effect and safety of eseitalopram combined with deanxit in treatment of patients with post-stroke depression. Methods Sixty-four patients with post-stroke depression who were admitted and treated in Third Hospital Affiliated to Qiqihar Medical University from March 2016 to March 2018 were randomly selected and were divided into the control group and the study group, with 32 cases in each group. Patients in two groups were all given routine treatment. At basis of routine treatment, the control group was given eseitalopram while the study group was given eseitalopram combined with deanxit. The treatment lasted for 6 weeks. Clinical curative effects of two groups were evaluated by Hamilton Depression（HAMD） Scale and National Institutes of Health Stroke Scale（NIHSS）. Nerve growth factor（NGF） and brain-derived neurotrophic factor（BDNF） were detected by enzyme- linked immunosorbent assay（ELISA）. Results Total effective rate of the study group was 93.8%, significantly higher than the control group（x2=5.379, P 〈 0.05）. HAMD score （15.54 ± 3.28, 12.35±2.57, 8.93 ± 3.17） （t=2.287, t=4.826, t=4.286） and NIHSS score （9.39 ±2.27, 7.31 ± 2.23, 5.95 ± 1.82） （t=2.304, t=2.745, t=2.643） of 2, 4, 6 weeks after treatment in the study group were both lower than those of the control group（P 〈 0.05）. After treatment, expression levels of serum NGF（13.37± 1.18） and BDNF（16.13±1.67） of patients in two groups were both lower than those before treatment（t= 11.533, P 〈 0.05）. And expression levels of serum NGF and BDNF of patients in the study group were both higher than those of the control group（t=7.172, P 〈 0.05）. Conclusion Escitalopram combined with deanxitean significantly improve depressive symptoms and neurological function of patients with post-stroke depression and improve expression level of nerve factor, which is worthy of clinical promotion.

关 键 词：卒中后抑郁 艾司西酞普兰 黛力新 临床疗效 

分 类 号：R749.1[医药卫生—神经病学与精神病学]